Find Funding Opportunities

Notice Clarification NIH BRAIN Initiative Institutional Letter RFA-NS-19-043 RFA-NS-19-044" K99/R00 - BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity" Notice Number: NOT-NS-20-094 Key Dates Release Date: August 5, 2020 Related Announcements RFA-NS-19-043 - BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Allowed) RFA-NS-19-044 - BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Required) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Center Complementary Integrative Health NCCIH) Purpose Notice to clarify placement inclusion the Institutional Letter RFA-NS-19-043 BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Allowed) RFA-NS-19-044- BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Required). current language reads: Section IV. Application Submission Information Project Information Institutional Letter: Applicants required attach letter the institution explaining the candidate's participation further goals the BRAIN Initiative Postdoctoral Career Transition Award, consistent the Notice NIH's Interest Diversity NOT-OD-18-210). letter the institution must on institutional letterhead scanned that institutional official signature visible. Name PDF-formatted letter Institutional_Ltr.pdf". letter limited 1 page. Due Forms-F application package changes, language been removed. Applicants should refer the PHS 398 Career Development Award Supplement Form instructions this letter. Please updated instructions below. language been modified read: Section IV. Application Submission Information PHS 398 Career Development Award Supplemental Form Environment Institutional Commitment Candidate Section outlined the SF424 form instructions, applicants diversity-related FOAs must complete 12. Description Candidate’s Contribution Program Goals” attachment: sponsoring institution must provide document institutional letterhead explains the candidate’s participation further goals the career development program promote diversityin BRAIN Initiative research. Description Candidate’s Contribution Program Goals” attachment must dated signed an institutional official. most cases, will the dean the chairman the department. signature must appear over signer's name title the end the statement. Attach information a PDF file. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-7966 Email: BRAINDIVERSITYK99R00@nih.gov

Solicitation Nominations the 2021 National Institute Neurological Disorders Stroke NINDS) Landis Award Outstanding Mentorship Notice Number: NOT-NS-20-093 Key Dates Release Date: July 29, 2020 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose Excellent mentorship superior training critical the development exceptional future scientists. recognize crucial role great mentors play the development future leaders neuroscience, National Institute Neurological Disorders Stroke NINDS) created Landis Award Outstanding Membership. award provides 100,000.00 direct costs) up five 5) faculty members, are considered be outstanding mentors trainers, help foster research career development additional students post-doctorates. NINDS hopes this tangible award impress upon scientific community a whole, faculty institutional leaders particular, high value NINDS places outstanding training mentorship the need faculty institutions emphasize reward dedication mentorship, addition outstanding research accomplishments. Selection this award based nomination those have first-hand knowledge an individual's outstanding mentorship. Current former trainees nominate faculty members have served their mentors. Faculty members nominated two more mentees then invited submit additional information needed the selection process. Eligible individuals this award must in tenure-track equivalent faculty position hold active NINDS R01, R35, U01, U54, P01,DP1, DP2 equivalent, 4-5 year duration NIH award, at least year left their grant June 2021. full details the award, the selection process be found at Landis Mentor Award. Because outstanding mentors exist each career stage, have different levels mentorship accomplishments, NINDS rotates eligibility requirements year. 2018, NINDS awards junior faculty mentors the 5th - 12th year the start their first tenure track equivalent position). 2019, NINDS awards mid-career faculty mentors the 13th - 20th year the start their first tenure track equivalent position). 2020, NINDS awards senior faculty 21 years more the start their first tenure track equivalent position). Landis Awardees be found Landis Mentor Award. this notice, NINDS invites nominations outstanding mentors are 5-12 years the start their first tenure-track equivalent faculty position i.e., start date their first tenure-track equivalent faculty position between 2008-2015). Nomination Nominations the NINDS Landis Mentor Award be accepted ONLY current former trainees the nominated individual. nominate current former mentor, individuals should visit Landis Mentor Award and complete nomination form by December 15, 2020. following information be requested: Nominator's name current position Name individual being nominated nominee) Current institution email address nominee Start date nominee's first tenure-track equivalent position Relationship nominator nominee dates mentorship, position nominator mentored nominee e.g. Former Current Graduate Student, Postdoctoral Fellow, etc.]) Statement describing basis the nomination. description should include: made/makes nominated individual exceptional mentor/trainer; are specific examples extraordinary dedication mentorship personally experienced witnessed; does individual to ensure trainees conduct highest quality research respect scientific premise, experimental design analysis; were specific nominee activities influenced nominator's growth a neuroscientist. a nomination be considered, of above information must provided via nomination form found at Landis Mentor Award. Selection NINDS consider number characteristics define outstanding mentorship guide final selection Landis Awardees. include: actively cultivating mentees pursuit scientific excellence, whether basic, translational, clinical research, rigor experimental design, analysis, interpretation; investing their mentee’s scientific professional development career progress, regardless their ultimate career interest; challenging mentees achieve full scientific potential, includes completion significant research projects meaningful contributions the biomedical research community; contributing excellence research training environments strengthening research enterprise inclusion people diverse backgrounds. is expected potential Landis awardees demonstrate support outstanding research training programs include diversity inclusion all career levels. Inquiries Please direct inquiries to: Stephen Korn National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email:korns@ninds.nih.gov

Notice Change Key Dates PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Notice Number: NOT-NS-20-086 Key Dates Release Date: July 10, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; September 9, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date September 10, 2020 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; October 8, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date October 9, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email: jettd@ninds.nih.gov

Notice Change Key Dates PAR-19-039 Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed)" Notice Number: NOT-NS-20-087 Key Dates Release Date: July 10, 2020 Related Announcements PAR-19-039 - Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-19-039 "Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; September 9, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; October 8, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice Change Key Dates PAR-19-040 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional)" Notice Number: NOT-NS-20-088 Key Dates Release Date: July 10, 2020 Related Announcements PAR-19-040 - Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-19-040 "Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; September 9, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; October 8, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)" Notice Number: NOT-NS-20-085 Key Dates Release Date: July 8, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) NOT-NS-18-072 - Rescinded - Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform applicants a change the Application Budgets PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". notice updates, supercedes replaces previous notice, NOT-NS-18-072 "Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Specifically, application budgets be reduced 2 million direct costs per yearto 1.75 million direct costs per year. notice be effective the October 8, 2020 receipt date. Change shown below bold italics. Currently Reads: Section II. Award Information Award Budget Application budgets not exceed 2.0 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. Modified Read: Section II. Award Information Award Budget Application budgets not exceed 1.75 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email:jettd@ninds.nih.gov

Notice Change Key Dates RFA-NS-20-030 Research Program Award R35 Clinical Trial Optional)" Notice Number: NOT-NS-20-092 Key Dates Release Date: July 7, 2020 Related Announcements RFA-NS-20-030 - Research Program Award R35 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates RFA-NS-20-030 "Research Program Award R35 Clinical Trial Optional)". July 31, 2020 receipt date been moved August 14, 2020. Changes shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates Letter Intent Due Date(s) July 1, 2020 Application Due Date(s) July 31, 2020 late applications be accepted this Funding Opportunity Announcement. applications due 5:00 PM local time applicant organization. Alltypes non-AIDS applicationsallowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date August 01, 2020 Modified Read: Part 1. Overview Information Key Dates Letter Intent Due Date(s) July 21, 2020 Application Due Date(s) August 14, 2020 late applications be accepted this Funding Opportunity Announcement. applications due 5:00 PM local time applicant organization. Alltypes non-AIDS applicationsallowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date August 15, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Anna Taylor, Ph.D.National Institute Neurological Disorders Stroke NINDS)Telephone: 301-827-3565Email:anna.taylor@nih.gov

Notice Participation PA-18-358, NINDS Exploratory Neuroscience Research Grant R21- Clinical Trial Optional)" Notice Number: NOT-MH-20-034 Key Dates Release Date: July 7, 2020 Related Announcements PA-18-358,NINDS Exploratory Neuroscience Research Grant R21- Clinical Trial Optional) Issued National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants NIMH's participation, effective immediately, PA-18-358, " NINDS Exploratory Neuroscience Research Grant R21- Clinical Trial Optional)" the next receipt date October 16, 2020. following sections PA-18-358 been updated reflect participation NIMH this Notice: Part 1. Overview Information Components Participating Organizations National Institute Neurological Disorders Stroke NINDS) National Institute Mental Health NIMH) Section Funding Opportunity Description Areas scientific interest the NIMH reflect Neuroscience areas priority detailed the NIMH Strategic Plan found within following divisions offices. Division Neuroscience Basic Behavioral Science DNBBS) supports research programs basic neuroscience, genetics, resource technology development, drug discovery. Examples priorities include are limited these topics: Discover novel mechanisms nervous system development across genes, proteins, cells circuitry) signaling properties underlie emergence cognition, emotion, social behavior. Develop use innovative strategies, including genome-wide comparative approaches, discover genes gene regulatory mechanisms underlying brain functions includingcognition, emotion, social behavior. Discover cellular molecular mechanisms whereby hormones immune molecules modulate signaling brain circuits relevant emotion regulation, cognition, social behavior. Develop empirically evaluate computational theoretical models address plasticity brain circuits during development impacting cognitive, affective, social behaviors. Research elucidate genomic risk factors underlie mental disorders. Division Translational Research DTR) supports research translates knowledge basic science discover etiology, pathophysiology, trajectory mental disorders develops effective interventions children adults. Examples priorities include are limited these topics: Delineate specific neural circuits contributing one more major mental disorders subtypes mental disorders. Identify mechanisms e.g., biological, behavioral, environmental) confer vulnerability psychiatric illnesses. Discover novel targets future therapeutic intervention identifying causal relationships between neural circuits symptom expression. Delineate neurobehavioral mechanisms responsible the development psychopathology, including critical sensitive periods brain development the effects sex, behavior, experience the brain. Assess mechanisms action efficacious interventions the brain bench, pre-clinical context, computational models. Division AIDS Research DAR) supports research basic clinical neuroscience HIV infection. Examples priorities include are limited these topics: Understand decipher a molecular level, HIV associated neuroimmune dysregulation impacts neuronal receptors, neuroendocrine milieu, neurotransmitters synaptic plasticity the context HIV anti-retroviral therapy. Pre-clinical research studies target neuroimmune dysregulation, blood brain barrier disruption altered neuronal circuitry individuals living HIV to decipher potential CNS toxicities associated anti-retroviral therapy other emergent treatments HIV cure. Support use state-of-the-art epi)genetic approaches identify validate viral host genetic factors influence pathophysiology manifestations HIV-induced CNS dysfunction. Define characterize HIV persistence the CNS the context suppressive highly active antiretroviral therapy foster translational research enable eradication HIV the brain. Office Technology Development Coordination OTDC): Supports basic applied research related the development scientific tools, technologies, approaches related brain behavioral research. Any Clinical Trial research submitted NIMH under R21 mechanism must follow guidance noted NIMH NOT-MH-19-006. is, NIMH supports hypothesis-driven mechanistic clinical trial studies basic and/or translational discovery research health human subjects in pathobiology, pathophysiology psychopathology mental disorders in HIV infection the central nervous system CNS). goal to address basic questions to interrogate concept biology, behavior, pathophysiology will provide insight to understanding mental health mental disorders. https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-t…. Inquiries Please direct inquiries to: Susan Koester, Ph.D.National Institute Mental Health NIMH)Telephone:301-443-3563Email: koesters@mail.nih.gov

Notice Clarification Application Types Allowed PAR-20-111 Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional)" Notice Number: NOT-NS-20-091 Key Dates Release Date: July 7, 2020 Related Announcements PAR-20-111 - Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to clarify Application Types Allowed PAR-20-111 "Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional). Activity Code section Part 1. Overview Information) been modified remove following text "U44Small Business Innovation Research SBIR) Cooperative Agreements - Phase II". text being removed be consistent Section II. Award Information stating only New Fast-Track) applications be accepted response this Funding Opportunity Announcement FOA). change be effective the August 11, 2020 receipt date subsequent due dates.Changes the FOA shown below. Currently Reads: Part 1. Overview Information Activity Code U44Small Business Innovation Research SBIR) Cooperative Agreements - Phase II U44Small Business Innovation Research SBIR) Cooperative "Agreement – Fast Track" Modified Read: Part 1. Overview Information Activity Code U44Small Business Innovation Research SBIR) Cooperative "Agreement – Fast Track" other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email:charles.cywin@nih.gov

Notice Change Key Dates PAR-18-618 NINDS Exploratory Clinical Trials Small Business R44 Clinical Trial Required)" Notice Number: NOT-NS-20-079 Key Dates Release Date: June 29, 2020 Related Announcements PAR-18-618 - NINDS Exploratory Clinical Trials Small Business R44 Clinical Trial Required) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-618 "NINDS Exploratory Clinical Trials Small Business R44 Clinical Trial Required)". Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date:April 5, 2021. Changes shown below bold italics. Currently Reads: Part 1. Overview Key Dates: Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Key Dates: Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Emily Caporello, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1778 Email:Emily.caporello@nih.gov